Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster-acting insulin aspart or insulin aspart: a secondary analysis of the CopenFast trial

被引：0
|
作者：
Soholm, J. C. [1 ,2 ]
Norgaard, S. K. [1 ,2 ]
Norgaard, K. [2 ,3 ]
Clausen, T. D. [1 ,2 ]
Damm, P. [1 ,2 ]
Mathiesen, E. [1 ,2 ]
Ringholm, L. [1 ,2 ]
机构：
[1] Rigshosp, Ctr Pregnant Women Diabet, Copenhagen, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[3] Steno Diabet Ctr, Herlev, Denmark
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
462
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [21] Double-blind mealtime faster-acting insulin aspart improves glycaemic control with superior reduction in postprandial glucose excursions vs insulin aspart in type 1 diabetes: onset® 1
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R. M.
    DIABETOLOGIA, 2016, 59 : S6 - S6
  • [22] Faster-Acting Insulin Aspart Improves Postprandial Glycemia vs. Insulin Aspart in Patients with Type 1 Diabetes Mellitus (T1DM)
    Heise, Tim
    Haahr, Hanne L.
    Jensen, Lene
    Erichsen, Lars
    Hompesch, Marcus
    DIABETES, 2014, 63 : A34 - A34
  • [23] Glycaemic efficacy and safety of mealtime faster-acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta-analysis of randomized controlled trials
    Pal, Rimesh
    Banerjee, Mainak
    Bhadada, Sanjay Kumar
    DIABETIC MEDICINE, 2021, 38 (03)
  • [24] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Stender-Petersen, Kirstine
    Hoevelmann, Ulrike
    Jacobsen, Jacob Bonde
    Nosek, Leszek
    Zijlstra, Eric
    Haahr, Hanne
    CLINICAL PHARMACOKINETICS, 2017, 56 (06) : 649 - 660
  • [25] Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
    Heise, Tim
    Zijlstra, Eric
    Nosek, Leszek
    Rikte, Tord
    Haahr, Hanne
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 208 - 215
  • [26] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Kirstine Stender-Petersen
    Ulrike Hövelmann
    Jacob Bonde Jacobsen
    Leszek Nosek
    Eric Zijlstra
    Hanne Haahr
    Clinical Pharmacokinetics, 2017, 56 : 649 - 660
  • [27] Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart vs insulin aspart in Japanese patients with type 1 diabetes
    Shiramoto, M.
    Nishida, T.
    Hansen, A.
    Haahr, H.
    DIABETOLOGIA, 2015, 58 : S403 - S403
  • [28] Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Subjects with Type 1 Diabetes Using CSII
    Bode, Bruce
    Hyveled, Liselotte
    Tamer, Soren Can
    Ybanez, Patria
    Demissie, Marek
    DIABETES, 2015, 64 : A253 - A253
  • [29] Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
    Zijlstra, Eric
    Demissie, Marek
    Graungaard, Tina
    Heise, Tim
    Nosek, Leszek
    Bode, Bruce W.
    CLINICAL ENDOCRINOLOGY, 2017, 86 : 46 - 46
  • [30] Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial
    Saravanan, P.
    Bowering, K.
    Case, C.
    Harvey, J.
    Reeves, M.
    Sampson, M.
    Strzinek, R.
    Bretler, D. M.
    Bang, R. B.
    Bode, B. W.
    DIABETIC MEDICINE, 2017, 34 : 21 - 21
12345